Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Tolerability of CKD-348(6) vs Co-administration of CKD-828, D097, and D337
NCT06112678Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan, Levamlodipine, rosuvastatin and ezetimibe in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Jan 2024; status: completed.
02
Drugs
telmisartanLevamlodipinerosuvastatinezetimibe
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT06112678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112678.